Role of hypertension in the cardiovascular-kidney-metabolic syndrome among black adults: The Jackson Heart Study.

IF 3.4 4区 医学 Q2 PERIPHERAL VASCULAR DISEASE
Lama Ghazi, Medha Dubal, Alain Bertoni, April Carson, Bessie A Young, Cora E Lewis, Chibuike J Alanaeme, Dayna A Johnson, Daichi Shimbo, Kathryn Foti, Lisandro D Colantonio, Milla Arabadjian, Rikki Tanner, Paul Muntner
{"title":"Role of hypertension in the cardiovascular-kidney-metabolic syndrome among black adults: The Jackson Heart Study.","authors":"Lama Ghazi, Medha Dubal, Alain Bertoni, April Carson, Bessie A Young, Cora E Lewis, Chibuike J Alanaeme, Dayna A Johnson, Daichi Shimbo, Kathryn Foti, Lisandro D Colantonio, Milla Arabadjian, Rikki Tanner, Paul Muntner","doi":"10.1038/s41371-025-01078-6","DOIUrl":null,"url":null,"abstract":"<p><p>The cardiovascular-kidney-metabolic (CKM) syndrome consists of four progressive stages and is characterized by the interaction of metabolic risk factors, chronic kidney disease (CKD), and cardiovascular disease (CVD). We assessed the prevalence of hypertension in CKM and its role in progression to more advanced stages. We included 2118 Black adults from the Jackson Heart Study without a history of coronary heart disease, heart failure, stroke or stage 0 CKM (normal weight, no metabolic risk factors or CVD) at baseline. Participants were categorized into CKD stage: Stage 1: overweight/obesity, abdominal obesity or dysfunctional adipose tissue without metabolic risk factors or subclinical CVD; Stage 2: metabolic risk factors (hypertension, diabetes, hypertriglyceridemia, metabolic syndrome or CKD); or Stage 3: subclinical CVD. We used Cox proportional hazards regression to estimate the hazard ratio (HR) of developing stage 4 CKM, defined by a CVD event, in participants with hypertension and stages 2 and 3 CKM. At baseline, 20.2, 69.1 and 10.6% of participants had stage 1, 2 and 3 CKM, respectively. Hypertension was the most common metabolic risk factor in participants with stage 2 and 3 CKM with a prevalence of 80 and 95%, respectively. Incidence rates (95%CI) of stage 4 CKM per 1000 person-years were 1.4 (0.4, 2.4) for stage 1 CKM, 7.5 (6.1, 8.9) for stage 2 CKM with hypertension, and 26.6 (19.8, 33.3) for stage 3 CKM with hypertension. The HRs (95% CI) for developing stage 4 CKM were 3.25 (1.56, 6.80) and 5.11 (2.05,12.78) among participants with hypertension and stage 2 and 3 CKM versus stage 1 CKM, respectively. Hypertension was associated with an increased risk for progression to stage 4 CKM among Black adults.</p>","PeriodicalId":16070,"journal":{"name":"Journal of Human Hypertension","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Human Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41371-025-01078-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

The cardiovascular-kidney-metabolic (CKM) syndrome consists of four progressive stages and is characterized by the interaction of metabolic risk factors, chronic kidney disease (CKD), and cardiovascular disease (CVD). We assessed the prevalence of hypertension in CKM and its role in progression to more advanced stages. We included 2118 Black adults from the Jackson Heart Study without a history of coronary heart disease, heart failure, stroke or stage 0 CKM (normal weight, no metabolic risk factors or CVD) at baseline. Participants were categorized into CKD stage: Stage 1: overweight/obesity, abdominal obesity or dysfunctional adipose tissue without metabolic risk factors or subclinical CVD; Stage 2: metabolic risk factors (hypertension, diabetes, hypertriglyceridemia, metabolic syndrome or CKD); or Stage 3: subclinical CVD. We used Cox proportional hazards regression to estimate the hazard ratio (HR) of developing stage 4 CKM, defined by a CVD event, in participants with hypertension and stages 2 and 3 CKM. At baseline, 20.2, 69.1 and 10.6% of participants had stage 1, 2 and 3 CKM, respectively. Hypertension was the most common metabolic risk factor in participants with stage 2 and 3 CKM with a prevalence of 80 and 95%, respectively. Incidence rates (95%CI) of stage 4 CKM per 1000 person-years were 1.4 (0.4, 2.4) for stage 1 CKM, 7.5 (6.1, 8.9) for stage 2 CKM with hypertension, and 26.6 (19.8, 33.3) for stage 3 CKM with hypertension. The HRs (95% CI) for developing stage 4 CKM were 3.25 (1.56, 6.80) and 5.11 (2.05,12.78) among participants with hypertension and stage 2 and 3 CKM versus stage 1 CKM, respectively. Hypertension was associated with an increased risk for progression to stage 4 CKM among Black adults.

高血压在黑人心血管-肾-代谢综合征中的作用:杰克逊心脏研究
心血管-肾代谢(CKM)综合征包括四个进行性阶段,其特点是代谢危险因素、慢性肾脏疾病(CKD)和心血管疾病(CVD)的相互作用。我们评估了CKM中高血压的患病率及其在进展到更晚期的作用。我们纳入了来自Jackson心脏研究的2118名黑人成年人,他们在基线时没有冠心病、心力衰竭、中风或0期CKM(体重正常,无代谢危险因素或心血管疾病)的病史。参与者被分为CKD阶段:1期:超重/肥胖,腹部肥胖或功能失调的脂肪组织,无代谢危险因素或亚临床心血管疾病;第二阶段:代谢危险因素(高血压、糖尿病、高甘油三酯血症、代谢综合征或CKD);或第三阶段:亚临床CVD。我们使用Cox比例风险回归来估计高血压和2期和3期CKM参与者发展为4期CKM的风险比(HR),由CVD事件定义。在基线时,20.2%、69.1和10.6%的参与者分别为1期、2期和3期CKM。高血压是2期和3期CKM参与者中最常见的代谢危险因素,患病率分别为80%和95%。4期CKM每1000人年的发病率(95%CI)为:1期CKM为1.4(0.4,2.4),2期CKM合并高血压为7.5(6.1,8.9),3期CKM合并高血压为26.6(19.8,33.3)。与1期CKM相比,高血压和2期和3期CKM患者发展为4期CKM的hr (95% CI)分别为3.25(1.56,6.80)和5.11(2.05,12.78)。在黑人成年人中,高血压与进展为4期CKM的风险增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Human Hypertension
Journal of Human Hypertension 医学-外周血管病
CiteScore
5.20
自引率
3.70%
发文量
126
审稿时长
6-12 weeks
期刊介绍: Journal of Human Hypertension is published monthly and is of interest to health care professionals who deal with hypertension (specialists, internists, primary care physicians) and public health workers. We believe that our patients benefit from robust scientific data that are based on well conducted clinical trials. We also believe that basic sciences are the foundations on which we build our knowledge of clinical conditions and their management. Towards this end, although we are primarily a clinical based journal, we also welcome suitable basic sciences studies that promote our understanding of human hypertension. The journal aims to perform the dual role of increasing knowledge in the field of high blood pressure as well as improving the standard of care of patients. The editors will consider for publication all suitable papers dealing directly or indirectly with clinical aspects of hypertension, including but not limited to epidemiology, pathophysiology, therapeutics and basic sciences involving human subjects or tissues. We also consider papers from all specialties such as ophthalmology, cardiology, nephrology, obstetrics and stroke medicine that deal with the various aspects of hypertension and its complications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信